English
Polski
Español
українська
Biosimilar drugs and burden of severe asthma
To what degree does the introduction of biosimilar drugs into the asthma treatment regimens reduce the burden of severe asthma? With Dr Paul O'Byrne.
2024-12-18
To what degree does the introduction of biosimilar drugs into the asthma treatment regimens reduce the burden of severe asthma? With Dr Paul O'Byrne.
Can the biologic treatment used in asthma promote permanent remission of the disease? With Dr Paul O'Byrne.
What percentage of patients treated with biologics for asthma develops resistance to monoclonal antibodies used in the therapy? With Dr Paul O'Byrne.
When does a patient with asthma exacerbation require mechanical ventilation and sedation? With Dr Paul O'Byrne.
Can an increased level of eosinophils in the nasal cytology of a person with chronic cough indicate eosinophilic bronchitis as its cause?
What is the typical time between starting the ACEI treatment and the occurrence of cough? How long should we wait for suspected ACEI-induced cough to resolve?
What is the difference between refractory and unexplained chronic cough?
How should we identify patients with mild asthma who really need regular treatment with ICS?
Should we offer biologic therapy to patients with nonsevere asthma?
